c-MET Non-Small Cell Lung Cancer (c-MET+ NSCLC)
c-MET Non-Small Cell Lung Cancer (c-MET+ NSCLC) Market

 C-Met is a tyrosine kinase receptor that is encoded in part by a mesenchymal-epidermal transition (MET) exon 14. Mutations in the MET gene can lead to increased c-MET signalling and oncogenic stimulation. Although c-MET mutation is rare, it is a targetable driver mutation.


Cellular-Mesenchymal Epithelial Transition Factor (C-Met) Mutated Non-small Cell Lung Cancer (NSCLC) Epidemiological Segmentation 

The Epidemiological Segmentation of Cellular-Mesenchymal Epithelial Transition Factor (C-Met) Mutated Non-small Cell Lung Cancer (NSCLC) in 7MM from 2017 to 2030 is segmented as:- 

  • Total Incident Cases of NSCLC patients
  • Total Incident Cases of NSCLC Patients by Histology
  • Total Diagnosed Cases of NSCLC Patients by Stages
  • Total Incident Cases of C-Met NSCLC
  • Treated Patient Pool of C-Met NSCLC 


Cellular-Mesenchymal Epithelial Transition Factor (C-Met) Mutated Non-small Cell Lung Cancer (NSCLC) Epidemiology 

  • Total incident cases of C-Met mutated NSCLC in 7MM in 2017 were 16,658C-Met accounted for around 4% of the total cases of NSCLC
  • The total cases of C-Met mutated NSCLC in the United States were 7,202  in 2017


Cellular-Mesenchymal Epithelial Transition Factor (C-Met) Mutated Non-small Cell Lung Cancer (NSCLC) Market

The market size of C-Met mutated NSCLC in 7MM in 2017 was USD 186 million.  


Cellular-Mesenchymal Epithelial Transition Factor (C-Met) Mutated Non-small Cell Lung Cancer (NSCLC) Market Drivers

  • Increasing Use of Biomarker Testing 
  • Increase in the Mutation Specific Trials Activity
  • Increasing Incidence of C-Met mutated NSCLC

 

Cellular-Mesenchymal Epithelial Transition Factor (C-Met) Mutated Non-small Cell Lung Cancer (NSCLC) Market Barriers

  • Cost-Effectiveness of Therapies
  • Small Patient Populations of C-Met mutated NSCLC
  • Cost of Therapies
  • Burden of Disease


Cellular-Mesenchymal Epithelial Transition Factor (C-Met) Mutated Non-small Cell Lung Cancer (NSCLC) Emerging Drugs

The emerging drugs of the Cellular-Mesenchymal Epithelial Transition Factor (C-Met) Mutated Non-small Cell Lung Cancer (NSCLC) market are 

  • Tepmetko (tepotinib)
  • Merestinib
  • Telisotuzumab Vedotin
  • JNJ-61186372 (JNJ-6372)
  • Canakinumab (ACZ885)
  • Cabozantinib
  • Sym015

And many others. 


Cellular-Mesenchymal Epithelial Transition Factor (C-Met) Mutated Non-small Cell Lung Cancer (NSCLC) Key Players

The key players in the Cellular-Mesenchymal Epithelial Transition Factor (C-Met) Mutated Non-small Cell Lung Cancer (NSCLC) market are

  • Novartis Pharmaceuticals
  • Merck KGaA
  • Eli Lilly and Company
  • AbbVie
  • Janssen Research & Development
  • Exelixis
  • Ipsen
  • Takeda
  • Symphogen

And many others.